720 related articles for article (PubMed ID: 9291044)
21. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan.
Kuwatsuru R; Kadoya M; Ohtomo K; Tanimoto A; Hirohashi S; Murakami T; Tanaka Y; Yoshikawa K; Katayama H
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S65-74. PubMed ID: 10608400
[TBL] [Abstract][Full Text] [Related]
22. Detectability of early brain meningitis with magnetic resonance imaging.
Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.
Kuhn MJ; Picozzi P; Maldjian JA; Schmalfuss IM; Maravilla KR; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Wolansky LJ; Gustafsson L; Essig M; Anzalone N
J Neurosurg; 2007 Apr; 106(4):557-66. PubMed ID: 17432704
[TBL] [Abstract][Full Text] [Related]
27. MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses.
Schima W; Saini S; Petersein J; Weissleder R; Harisinghani M; Mayo-Smith W; Hahn PF
J Magn Reson Imaging; 1999 Jul; 10(1):80-3. PubMed ID: 10398981
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
29. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Runge VM; Parker JR; Donovan M
Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
[TBL] [Abstract][Full Text] [Related]
31. Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging.
Gehl HB; Bourne M; Grazioli L; Möller A; Lodemann KP
Eur Radiol; 2001; 11(2):187-92. PubMed ID: 11218012
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
33. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with magnetic resonance imaging at 1.5 tesla.
Runge VM; Wells JW
Invest Radiol; 1996 Jul; 31(7):395-400. PubMed ID: 8818779
[TBL] [Abstract][Full Text] [Related]
34. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
35. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
Runge VM; Biswas J; Wintersperger BJ; Baumann SS; Jackson CB; Herborn CU; Patel T
Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
[TBL] [Abstract][Full Text] [Related]
37. High-dose applications of gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Thomas GS
Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
[TBL] [Abstract][Full Text] [Related]
38. Delayed Gadolinium-enhanced MR Imaging of Cartilage: A Comparative Analysis of Different Gadolinium-based Contrast Agents in an ex Vivo Porcine Model.
Kang Y; Choi JY; Yoo HJ; Hong SH; Kang HS
Radiology; 2017 Mar; 282(3):734-742. PubMed ID: 27649101
[TBL] [Abstract][Full Text] [Related]
39. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
